Maximal killing of lymphoma cells by DNA damage-inducing therapy requires not only the p53 targets Puma and Noxa, but also Bim
Lina Happo, Mark S Cragg, Belinda Phipson, Jon M Haga, Elisa S Jansen, Marco J Herold, Grant Dewson, Ewa M Michalak, Cassandra J Vandenberg, Gordon K Smyth, Andreas Strasser, Suzanne Cory, Clare L Scott
Blood | AMER SOC HEMATOLOGY | Published : 2010
Awarded by National Health and Medical Research Council (Australia)
Awarded by Leukemia and Lymphoma Society (New York)
Awarded by National Cancer Institute (National Institutes of Health)
Awarded by NATIONAL CANCER INSTITUTE
This work was supported by fellowships and grants from the National Health and Medical Research Council (Australia; program #257502; R.D. Wright Biomedical CDA 406675), the Leukemia and Lymphoma Society (New York; SCOR grant #7015; CLS Special Fellow Grant 3209-04), the National Cancer Institute (National Institutes of Health; CA 80188 and CA 43540), the Leukemia and Lymphoma Research UK (fellowship to M.S.C.), the DFG (German Science Foundation) (fellowship to M.J.H.), the Leukemia Foundation Australia (PhD scholarship to L.H.), and the University of Melbourne (PhD scholarship for B.P.).